Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary Rehabilitation in Nintedanib Treated IPF
NCT03717012Phase 4Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change From Baseline in the 6 Minute Walk Test Distance at 12 weeks. Started Nov 2018; status: terminated.
Beyond the preview
Go deeper on NCT03717012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03717012.